You are here: Industry Insights > gilead

News List

Gilead agrees to acquire Immunomedics for $21bn pharmaceutical-technology
September 15, 2020
Gilead Sciences has signed a definitive agreement to acquire cancer therapies developer Immunomedics for a total consideration of approximately $21bn, or $88 per share.
EU OKs paediatric use of Gilead's Epclusa pharmatimes
September 03, 2020
The European Commission (EC) has expanded marketing authorisation for Gilead's Epclusa (sofosbuvir/velpatasvir/sofosbuvir) to include the treatment of children with chronic hepatitis C infection (HCV).
FDA expands emergency use authorisation for remdesivir to treat all COVID-19 patients europeanpharmaceuticalreview
September 02, 2020
The FDA has expanded the Emergency Use Authorisation for Veklury (remdesivir) to treat all hospitalised patients with COVID-19.
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program expresspharma
September 02, 2020
Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop JTX-1811.
FDA grants EUA for Gilead’s remdesivir to treat Covid-19 pharmaceutical-technology
September 01, 2020
The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Gilead Sciences’ Veklury (remdesivir) to treat all hospitalised patients with Covid-19.
Gilead, AstraZeneca and Pfizer may be winners in race for COVID-19 therapeutics and vaccines: GlobalData expresspharma
August 31, 2020
More than 1,200 therapeutics and vaccines have entered the research and development (R&D) pipeline since January 2020, according to GlobalData, and that number grows every week.
Remdesivir has only marginal benefit for moderate COVID-19 patients expresspharma
August 24, 2020
The 600-patient analysis found that moderately-ill patients treated with Remdesivir for up to five days had significantly higher odds of improvement compared to a 10-days course.
US FDA declines approval for Gilead’s rheumatoid arthritis drug, Filgotinib expresspharma
August 20, 2020
The US drug regulator has issued a complete response letter requesting data from the MANTA and MANTA-RAy studies and expressing concerns regarding the overall benefit/risk profile of the drug.
Gilead and Tango Therapeutics partner for targeted cancer therapies pharmaceutical-technology
August 19, 2020
Gilead Sciences has collaborated with Tango Therapeutics to discover, develop and commercialise targeted immune evasion therapies for cancer patients.
Gilead seeks full approval for remdesivir from US FDA for COVID-19 treatment expresspharma
August 12, 2020
To boost the drug’s availability globally, Gilead has signed multiple manufacturing and supply deals, including with Pfizer and Britain’s Hikma Pharmaceuticals.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page